-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Maintenance of the PD-L1 inhibitor durvalumab is recommended for patients with inoperable stage III non-small cell lung cancer ( NSCLC
Maintenance of the PD-L1 inhibitor durvalumab is recommended for patients with inoperable stage III non-small cell lung cancer ( NSCLC
The study included patients with stage III NSCLC who received durvalumab maintenance therapy from July 2017 to July 2019
The study included patients with stage III NSCLC who received durvalumab maintenance therapy from July 2017 to July 2019
The study included 121 patients with stage III NSCLC who received durvalumab consolidation, 50.
The rates of disease progression in patients with PD-L1 expression levels of 50-100%, 1-49%, and <1% were 16.
The median PFS of patients with PD-L1 expression levels 50-100%, 1-49%, and <1% were 16.
PFS
The median OS was 17.
The median OS was 17.
OS
Multivariate analysis showed that, when adjusted for age, sex, race, smoking status, histological subtype of NSCLC, tumor size, and lymph node status, PD-L1 expression level >50% was only associated with improved PFS (HR = 0.
Multivariate analysis showed that, when adjusted for age, sex, race, smoking status, histological subtype of NSCLC, tumor size, and lymph node status, PD-L1 expression level >50% was only associated with improved PFS (HR = 0.
In conclusion, the study showed that patients with PD-L1 expression levels >50% had significantly longer progression-free survival and overall survival than patients with low PD-L1 expression levels
In conclusion, the study showed that patients with PD-L1 expression levels >50% had significantly longer progression-free survival and overall survival than patients with low PD-L1 expression levels
Original source:
Jazieh K, Gad M, Saad A, Wei W, Pennell NA.
Jazieh K, Gad M, Saad A, Wei W, Pennell NA.
Tumor PD-L1 expression is associated with outcomes in stage 3 NSCLC patients treated with consolidation durvalumab.
Transl Lung Cancer Res 2021;10(7):3071-3078.
doi : 10.
21037/tlcr-21-249
Leave a message here
